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CHARGE syndrome [coloboma of the eye, heart defects, atresia
of the choanae, retardation of growth and/or development,
genital and/or urinary abnormalities, and ear abnormalities
(including deafness)] is a genetic disorder characterized by a
specific and a recognizable pattern of anomalies. De novo muta-
tions in the gene encoding chromodomain helicase DNA binding
protein 7 (CHD7) are the major cause of CHARGE syndrome.
Here, we review the clinical features of 379 CHARGE
patients who tested positive or negative for mutations in CHD7.
We found that CHARGE individuals with CHD7 mutations more
commonly have ocular colobomas, temporal bone anomalies
(semicircular canal hypoplasia/dysplasia), and facial nerve pa-
ralysis compared with mutation negative individuals. We also
highlight recent genetic and genomic studies that have provided
functional insights into CHD7 and the pathogenesis of CHARGE
syndrome.  2010 Wiley-Liss, Inc.
Key words: CHARGE syndrome; CHD7; chromodomain
helicase DNA binding protein 7; review
INTRODUCTION
CHARGE syndrome (OMIM #214800) is a rare (incidence
1:10,000) [Jongmans et al., 2006; Lalani et al., 2006], nonrandom
combination of multiple anomalies. The pattern of anomalies now
associated with CHARGE syndrome was described independently
by Hittner et al. [1979] and Hall [1979], though it was Pagon et al.
[1981] who formally defined the pattern and coined the acronym
CHARGE to summarize its major features. In its early delineation
Pagon et al. [1981] referred to the pattern as an ‘‘Association’’; now
with its recognizable pattern and definition CHARGE is referred to
as a syndrome. The major clinical features of CHARGE syndrome
are ocular coloboma, heart malformations, atresia of the choanae,
retardation of growth, genital hypoplasia, and ear abnormalities.
Numerous other less consistent features, including hyposmia, cleft
lip/palate, and tracheoesophageal fistula, are also reported. Many of
these features, including genital hypoplasia, cleft palate, and heart
defects, are shared by other multiple anomaly syndromes such as
22q11.2 deletion [Sullivan 2008], Kallmann [Ogata et al., 2006; Kim
et al., 2008; Jongmans et al., 2009], and Treacher Collins [Dixon
et al., 2007]; however, CHARGE syndrome is considered unique in
its combination of these features with distinctive inner and outer
ear defects and optic colobomas.
The life expectancy of patients with CHARGE syndrome
varies widely, with individuals living anywhere from 5 days
[Issekutz et al., 2005] to at least 46 years [Jongmans et al., 2006].
Actuarial analysis of survival in children with CHARGE showed a
70% survival rate to 5 years of age, with the highest rate of mortality
in the first year of life. The rate of mortality is highest in infants
with a combination of choanal atresia and heart defects or tracheo-
esophagal fistula. Prevalent feeding and swallowing difficulties as
well as gastroesophagal reflux also contribute to CHARGE infant
mortality and may also contribute to overall mortality in all
CHARGE patients [Blake et al., 1998].
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Since the discovery in 2004 of chromodomain helicase DNA
binding (CHD7) as a causative gene in CHARGE, several studies
have attempted to define genotype– phenotype correlations and to
determine the overall contribution of CHD7 mutations to various
CHARGE features. In this study, we reviewed all manuscripts
published in English and indexed in PubMed from 2004 to 2009
in which patients with CHARGE features were tested for CHD7
mutation status. Detailed clinical information for mutation-posi-
tive patients is listed in Table I and mutation-negative patients in
Table II. Only those manuscripts which contained clinical infor-
mation and mutation status were included, and care was taken to
note the presence or absence of a particular clinical feature only
when evaluation for that condition was explicitly stated, to mini-
mize effects of under-reporting. We used a chi-square test to
identify statistically significant differences in the frequencies of
each clinical feature between mutation- positive and mutation-
negative individuals (Table III).
We found 25 studies in which 379 individuals with CHARGE
features were tested for CHD7 mutations. Of the 379 individuals
tested, 254 (67%) were CHD7 mutation-positive, whereas 125
(33%) were mutation-negative. It is important to note that not
all patients met full CHARGE diagnosis by Blake or Verloes clinical
criteria [Blake et al., 1998; Verloes, 2005], and not all studies
provided full clinical information on every individual. Methods
of mutation testing varied across sites, but all included full sequenc-
ing of coding exons. Not all individuals were tested for CHD7 gene
exonic deletions/duplications, so these types of mutations are likely
to be under-represented here. Nevertheless, these reports were
useful for analyzing potential differences in clinical phenotype
between mutation-positive and mutation-negative patients, and
for estimating the overall prevalence of each feature within
CHARGE.
Most (67%) (Table I) clinically diagnosed CHARGE patients had
pathogenic mutations in the gene encoding CHD7, located on
chromosome 8q12.1. Of the CHD7 mutations reported thus far,
approximately 72% are nonsense or frameshift, 13% are splice site,
and 10% are missense (Table IV). CHD7 mutations are reported
throughout the entire coding sequence of the gene and do not
appear to cluster in any meaningful way. Recurrent mutations are
rare, and clear genotype–phenotype correlations have not been
recognized, even among patients with identical CHD7 mutations
[Jongmans et al., 2006, 2008; Lalani et al., 2006]. The majority of
CHD7 mutations are predicted to be loss of function, likely leading
to an aberrant mRNA targeted for degradation via nonsense-
mediated decay. Therefore, haploinsufficiency for CHD7 is the
most likely pathogenic mechanism underlying CHARGE syn-
drome. This mechanism is supported by mouse studies in which
homozygosity for Chd7 loss-of-function mutations result in em-
bryonic lethality and heterozygous Chd7 mice display phenotypic
features similar to those associated with CHARGE syndrome
[Bosman et al., 2005; Hurd et al., 2007].
While the majority of CHD7 disruptions are nonsense or frame-
shift mutations, chromosomal abnormalities have also been re-
ported, including an interstitial deletion of 8q12.2-q13 [Arrington
et al., 2005] and a balanced translocation disrupting 8q12 [Johnson
et al., 2006]. Several chromosomal abnormalities not involving
CHD7 have also been reported to confer a phenotype similar to
those seen in CHARGE patients [Clementi et al., 1991; North
et al., 1995; Wieczorek et al., 1997; De Krijger et al., 1999; Lev
et al., 2000].
Recent work indicates that CHARGE patients without
detectable single-base mutations may have heterozygous deletions
of CHD7 [Wincent et al., 2009]. In fact, CHD7 was originally
identified as the causative gene in CHARGE syndrome due to
detection of a deletion by array-CGH [Vissers et al., 2004]. In one
exceptional case, deletion of a portion of CHD7 was caused by an
Alu retrotransposon [Udaka et al., 2007]. Alterations in exon copy
number have been reported, but they represent only a small fraction
of the reported disruptions of CHD7 [Bergman et al., 2008].
The minority (33%) of CHARGE patients have no identifiable
mutation in CHD7, thus the underlying etiology remains undeter-
mined. These cases could be explained by mutations in coding
(deletions or duplications) or noncoding regions of CHD7 such as
50 or 30 untranslated regions, introns, or critical regulatory ele-
ments. There may also be locus heterogeneity in CHARGE, but no
other convincing chromosomal regions or candidate genes have
emerged.
Almost all cases of CHARGE syndrome are sporadic; however,
a small number of cases of familial CHARGE syndrome and
parent-to-child transmission of CHD7 mutations have been
reported [Lalani et al., 2006; Delahaye et al., 2007; Jongmans
et al., 2008; Vuorela et al., 2008; Wincent et al., 2008; Pauli
et al., 2009]. In these cases, parents generally have a mild CHARGE
phenotype or are asymptomatic, whereas their children display
more severe defects. Somatic mosaicism for a CHD7 mutation was
described in an asymptomatic mother of two affected siblings
[Jongmans et al., 2008]. Germ cell mosaicism was also described
in an asymptomatic, father of two affected children [Pauli et al.,
2009]. It therefore seems that in cases of parental transmission of
CHD7 mutations, parents with the mutations are mildly affected or
asymptomatic and it is only their children who display the full
spectrum of CHARGE features.
CHD7 mutations have also been reported in patients diagnosed
with conditions that have significant clinical overlap with
CHARGE, including Kallmann [Ogata et al., 2006; Kim et al.,
2008; Jongmans et al., 2009], Omenn-like [Gennery et al., 2008],
and 22q11.2 deletion syndromes [Sanka et al., 2007]. These findings
imply that patients presenting with features of these syndromes, but
lacking typical molecular findings, should be examined for clinical
signs of CHARGE syndrome and tested for CHD7 mutations. These
discoveries also raise the possibility that CHD7 mutations
may underlie the pathogenesis of more human phenotypes than
previously appreciated, including isolated congenital defects. Large
-scale mutational analysis of CHD7 in developmental disorders
involving organ systems affected in CHARGE are needed to explore
this possibility further.
CLINICAL FEATURES OF CHARGE SYNDROME
From the 254 CHD7 mutation-positive individuals reported since
2004, the most common clinical findings were temporal bone
anomalies (98%), external ear malformations (91%), and hearing
loss (89%) (Table III). About three fourths of patients had one or
more of the following: coloboma, heart malformations, and delayed
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growth and development (Table III). Between 61% and 62% of
CHARGE individuals had genital hypoplasia and/or urogenital
abnormalities, and 38% had choanal atresia/stenosis and/or facial
nerve palsy (Table III). Less commonly reported were cleft lip and/
or palate (33%) and tracheoesophageal fistula (19%). In the
following sections, we compare the clinical findings associated with
CHARGE syndrome in CHD7 mutation-positive and mutation-
negative individuals.
Ocular Defects
Colobomas typically involving the choroid, retina, and optic nerve
are the major ophthalmic manifestations associated with CHARGE
syndrome. Colobomas were more common in mutation-positive
(75%) than in mutation-negative (65%) individuals. Colobomas
are commonly bilateral, and can involve chorioretina, and optic
nerve [Tellier et al., 1998; Aramaki et al., 2006; Jongmans et al., 2006;
Alazami et al., 2008; McMain et al., 2008]. Iris, eyelid, and optic disc
colobomas are described with less frequency [Aramaki et al., 2006;
Jongmans et al., 2006; McMain et al., 2008]. Microphthalmos, optic
nerve hypoplasia, myopia, and strabismus are also reported
[Aramaki et al., 2006; Jongmans et al., 2006; Lalani et al., 2006;
Delahaye et al., 2007; Alazami et al., 2008; Wincent et al., 2008;
Jyonouchi et al., 2009], but frequencies of these malformations were
not compared in our study. Typical CHARGE colobomas produce
field defects in the upper quadrant and are often associated with
significant refractive errors, severe myoptic astigmatism, anisome-
tropia, microphthalmos, microcornea, and reduced visual acuity
[Tellier et al., 1998; Aramaki et al., 2006; Jongmans et al., 2006;
Delahaye et al., 2007; Alazami et al., 2008; McMain et al., 2008].





WincentVissers Felix Lalani Bergman
Coloboma 6/7 2/2 30/43 30/53 6/9
Heart malformations 5/7 9/9 30/42 36/53 6/9
Choanal atresia 3/7 1/2 23/39 23/53 2/9
Retarded growth 7/7 3/3 ND 14/14 7/9
Developmental delay 7/7 ND ND 31/31 6/9
Genital hypoplasia 5/7 2/3 26/39 9/9 4/8
Ear abnormalities including deafness 7/7 3/3 36/38 39/47 4/8
Temporal bone anomalies 5/5 ND 9/10 5/11 2/2
External ear malformations ND ND 39/42 ND 7/9
Facial nerve palsy 2/7 ND 13/39 4/47 0/9
Cleft lip and/or Cleft palate 4/7 8/9 9/41 12/53 1/9
Tracheoesophageal fistula ND ND 3/40 5/5 ND
Urogenital abnormalities ND ND 26/39 8/8 4/8
Frequencies are represented as the number of individuals with a particular feature/the total number of individuals tested. ND, not done.
TABLE III. Comparison of Clinical Features in CHD7 Mutation-Positive Versus Mutation-Negative Individuals
Syndrome feature CHD7 Mutation Positive CHD7 Mutation Negative P-value
Coloboma 190/253 (75%) 74/114 (65%) 0.044
Heart malformations 193/250 (77%) 86/120 (72%) 0.247
Choanal atresia 95/247 (38%) 52/110 (47%) 0.118
Retarded growth 101/141 (72%) 31/33 (94%) 0.007
Developmental delay 107/141 (76%) 44/47 (94%) 0.008
Genital hypoplasia 116/187 (62%) 46/66 (70%) 0.265
Ear abnormalities including deafness 198/223 (89%) 83/103 (86%) 0.538
Temporal bone anomalies 94/96 (98%) 21/28 (75%) 0.00004
External ear malformations 214/235 (91%) 46/51 (90%) 0.845
Facial nerve palsy 72/187 (39%) 19/102 (19%) 0.0005
Cleft lip and/or Cleft palate 79/242 (33%) 34/119 (29%) 0.433
Tracheoesophageal fistula 35/185 (19%) 8/45 (18%) 0.860
Urogenital abnormalities 86/142 (61%) 38/55 (69%) 0.266
Significant P-values as calculated by Chi-square test are in bold.
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Heart Defects
A wide variety of heart defects is reported as part of CHARGE
syndrome, highlighting the variable nature of its clinical presenta-
tion. We found that CHD7 mutation-positive and mutation-
negative patients were equally likely to have congenital heart
malformations (77% vs. 72%, respectively). Tetralogy of Fallot,
characterized by ventricular septal defects (VSD), pulmonary
stenosis, right ventricular hypertrophy, and an overriding aorta,
is frequently reported in CHARGE [Lin et al., 1987; Wyse et al.,
1993; Tellier et al., 1998; Jongmans et al., 2006; Lalani et al., 2006].
Each of the individual constituents of tetralogy of Fallot as well as
patent ductus arteriosis (PDA), atrial septal defects (ASD), and
solitary septal defects are reported, in various combinations [Lin
et al., 1987; Wyse et al., 1993; Tellier et al., 1998; Aramaki et al., 2006;
Jongmans et al., 2006; Lalani et al., 2006; Delahaye et al., 2007;
Alazami et al., 2008; Wincent et al., 2008; Wright et al., 2009].
Double outlet right ventricle and hypoplastic left/right heart are
also sometimes noted [Jongmans et al., 2006; Van de Laar et al.,
2007]. Aortal defects, including overriding aorta, right descending
aorta, and right aortic arch are reported individually and in
combination with other heart defects [Aramaki et al., 2006; Jong-
mans et al., 2006; Van de Laar et al., 2007; Alazami et al., 2008].
The literature regarding various heart malformations in patients
clinically suspected of having CHARGE syndrome is broad. Since
the development of CHD7 mutation screening, most information
on heart defects draws from CHD7 mutation-positive patients.
However, detailed reports of heart defects were published before the
availability of CHD7 mutation testing [Lin et al., 1987; Tellier et al.,
1998] and the heart defects of mutation-negative individuals are
rarely considered in detail in the literature. Therefore, it is difficult
at this time to accurately assess the frequencies of specific heart
defects between mutation-positive and mutation-negative patients.
However, Lalani et al. [2006] compared the frequency of several
specific heart defects between the two groups and found that
mutation-positive individuals were significantly more likely to
have PDA, but not tetralogy of Fallot, septal defects, or outflow
tract defects. More studies, with detailed analysis of heart malfor-
mations in both mutation-positive and mutation-negative
patients, are needed to further address any phenotypic differences
in heart defects between these two groups.
Choanal Atresia
CHD7 mutation-positive and mutation-negative patients did not
differ in the likelihood of having choanal atresia or stenosis (38% vs.
47%, respectively). Interestingly, the incidence of choanal atresia
varies depending upon the incidence of cleft lip/palate, as the choanae
are usually normal when clefting is present [Aramaki et al., 2006;
Jongmans et al., 2006]. Breathing difficulties are reported in approxi-
mately half of neonatal cases [Jongmans et al., 2006]. About 19% of
CHD7 mutation-positive CHARGE syndrome patients also present
with tracheoesophageal (TE) fistula (Table III), an abnormal con-
nection between the trachea and esophagus leading to feeding
difficulties and aspiration in babies which is typically corrected
surgically [White et al., 2005; Aramaki et al., 2006; Jongmans
et al., 2006; Lalani et al., 2006; Jyonouchi et al., 2009].
Growth and Developmental Delays
Growth defects, including short stature and low birth weight, are
reported in CHARGE patients and are typically of postnatal
onset [Aramaki et al., 2006; Jongmans et al., 2006; Lalani et al.,
2006; Jyonouchi et al., 2009]. Growth defects associated with
CHARGE rarely appear to correlate with deficiencies in pituitary
hormones including growth hormone (9% of patients) and thyroid
stimulating hormone (one incidence) and not with adrenocortico-
tropic hormone [Pinto et al., 2005; Aramaki et al., 2006; Asakura
et al., 2008]. Factors contributing to postnatal growth delays
include feeding and swallowing difficulties, gastroesophagal
reflux, olfactory dysfunction, cardiac dysfunction, and poor nutri-
tion. Additionally, due to many medical complications of CHARGE
syndrome, patients may be extensively hospitalized for surgery and
this may contribute to delayed growth. Surprisingly, we found that
delays in growth were more common in CHD7 mutation-negative
individuals (94%) than in mutation-positive individuals (72%)
(Table III). This difference was unexpected, and may reflect
patterns of data collection or reporting. Alternatively, CHD7
mutation negative patients may have different genetic etiologies
which predispose them to more significant growth delays.
A wide range of developmental symptoms, from mild speech
delay to severe intellectual disability without speech, has also been
reported in CHARGE [Jongmans et al., 2006; Delahaye et al., 2007;
Udaka et al., 2007; Alazami et al., 2008; Wright et al., 2009]. As with
growth delays, we found that significantly fewer mutation-positive
individuals (76%) were reported to have developmental delays
compared to mutation-negative (94%) individuals. As yet, there is
no comprehensive information about long-term cognitive and
functional outcomes between mutation-positive and mutation-
negative individuals. Nonetheless, it will be interesting to determine
whether the CHD7 mutation-negative cohort of individuals has
distinct genetic or environmental etiologies to predispose them to
more severe developmental and growth delays.
Endocrine and Urogenitary Anomalies
Hypogonadotropic hypogonadism and delayed puberty are
commonly reported features in CHARGE patients. Urogenital
abnormalities, including genital hypoplasia, were observed in
many (61%) CHARGE patients. These defects are less commonly
TABLE IV. Frequencies of the Various Types of Reported CHD7










Splice site 23 10
Whole-gene or chromosomal deletion 3 1
Exonic deletion 7 3
Chromosomal rearrangement 2 1
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reported in females; thus, the use of urogenital anomalies as a
diagnostic feature of CHARGE syndrome is biased towards males.
Micropenis and/or cryptorchidism are commonly diagnosed in
male patients. Female urogenital defects diagnosed in CHARGE
syndrome include hypoplasia of the uteris and labia. Some females
also experience pubertal failure [Jongmans et al., 2006]. We found
no statistically significant differences in the frequency of genital
hypoplasia or urogenital abnormalities in mutation-positive (61%)
versus mutation-negative (69%) individuals. Abnormalities in the
gonadotropic axis, including deficiencies in luteinizing hormone
(LH), follicle-stimulating hormone (FSH), testosterone, and estra-
diol, are frequently reported in CHARGE and are likely to contri-
bute to delayed puberty and impaired urogenital development
[Jongmans et al., 2006; Udaka et al., 2007; Asakura et al., 2008].
In one study, deficiency for gonadotropins (LH and FSH) was
found in 81% of males and in 93% of females analyzed [Jongmans
et al., 2006]. Stimulation by gonadotropin releasing hormone
(GnRH) had variable effects in males, while females had little to
no response to stimulation [Pinto et al., 2005; Ogata et al., 2006].
Developmental Abnormalities of the Ear
For clarity, we divided the ear abnormalities in individuals with
CHARGE into three separate types, based on reporting patterns
across all 25 studies: (a) deafness, (b) inner ear malformations
including semicircular canal dysplasia/hypoplasia, and (c) external
ear abnormalities. Hearing loss was equally common among
CHD7 mutation-positive (89%) and mutation-negative (86%)
individuals. Hearing loss can be conductive in nature owing to
structural anomalies of the inner ear, sensorineural due to defi-
ciencies in cranial nerve VIII function, or mixed conductive/
sensorineural [Edwards et al., 2002]. External ear malformations
were equally common in mutation-positive (91%) and mutation-
negative (90%) individuals. These malformations include lowset
ears, asymmetric ear shape or size, and small/absent lobes
[Jongmans et al., 2006; Lalani et al., 2006]. The outer ear often
takes on a characteristic ‘‘cup’’ shape in affected patients.
Inner ear anomalies detected by temporal bone CT or skull X-ray
were much more common in mutation-positive (98%) versus
mutation-negative (75%) individuals (Table III). These anomalies
include semicircular canal hypoplasia/aplasia, cochlear hypoplasia,
and Mondini malformation [Aramaki et al., 2006; Jongmans et al.,
2006; Lalani et al., 2006; Delahaye et al., 2007; Udaka et al., 2007;
Writzl et al., 2007]. Inner ear malformations are the most highly
penetrant clinical feature reported in CHARGE, with only two
individuals having CHD7 mutations and normal temporal bone CT
scans [Lalani et al., 2006; Wincent et al., 2008]. Balance disturbances
and vestibular areflexia, associated with deficiencies in vestibular
function due to malformation or agenesis of the semicircular canals,
have been previously noted as one of the most consistent features of
CHARGE syndrome [Jongmans et al., 2006; Delahaye et al., 2007].
Central Nervous System and Cranial
Nerve Anomalies
CNS anomalies are also reported in CHARGE patients and are
considered by Blake et al. [1998], to be a major diagnostic criterion.
Unilateral and bilateral hypoplasia of the olfactory bulb and/or
arhinencephaly are most commonly reported in CHARGE, and
may contribute to hyposmia or anosmia [Sanlaville et al., 2006;
Asakura et al., 2008]. Other defects, such as agenesis of the corpus
callosum, cerebellar hypoplasia, hydrocephaly, and atrophy of the
cerebral cortex have also been reported. Seizures are also observed
in CHARGE patients [Jongmans et al., 2006]. There was inadequate
information about CNS findings for many individuals in the reports
we reviewed, precluding accurate comparison between mutation-
positive and mutation-negative cases.
Defects in several cranial nerves have been reported in
CHD7 mutation-positive individuals. Although olfactory dysfunc-
tion is most likely a result of hypoplasia/absence of the olfactory
bulbs, defects in cranial nerve I may also contribute to olfactory
dysfunction. Cranial nerve VI defects are reported, and lead
to internal strabismus [Bergman et al., 2008]. Facial palsy and
asymmetry, indicative of anomalies in cranial nerve VII, are often
seen in CHARGE patients [Aramaki et al., 2006; Jongmans et al.,
2006, 2008; Udaka et al., 2007; Wincent et al., 2008; Pauli et al.,
2009]. We found that mutation-positive individuals were far more
likely to have facial palsy (39%) than mutation-negative (19%)
CHARGE individuals. Further studies will help to determine
whether this reflects an underlying bias in clinical data reporting
or a real biological effect of CHD7 function.
Deficiencies in cranial nerve VIII function result in sensorineural
deafness and disturbances in balance and vestibular function
[Johnson et al., 2006; Udaka et al., 2007; Bergman et al., 2008; Lee
et al., 2009]. Swallowing difficulties due to dysfunction of cranial
nerves IX, X, and/or XI are also a common feature of CHARGE
syndrome [Udaka et al., 2007; Wincent et al., 2008; Jyonouchi et al.,
2009].
Facial Anomalies and Clefting
Typical facial features of CHARGE syndrome include a square-
shaped face with a wide nasal bridge and small mouth [Sanlaville
and Verloes 2007]. We found that cleft lip and/or palate were
similarly present in mutation-positive (33%) versus mutation-
negative (29%) individuals [Aramaki et al., 2006; Jongmans
et al., 2006; Lalani et al., 2006; Wincent et al., 2008; Jyonouchi
et al., 2009].
Spinal Defects and Limb/Skeletal Abnormalities
Scoliosis is reported in many children with CHARGE, and often
includes structural abnormalities of the vertebrae [Jongmans
et al., 2006]. Polymorphisms in CHD7 have been associated with
susceptibility to idiopathic scoliosis [Gao et al., 2007]. Other spinal
defects, including spina bifida occulta and kyphosis, are also present
in CHARGE [Jongmans et al., 2006; Delahaye et al., 2007].
Recent reports have shed light into some of the limb abnor-
malities present in CHARGE patients. Two reports have confirmed
tibial agenesis, both with CHD7 mutations [Van de Laar et al.,
2007; Alazami et al., 2008]. The authors of one of these
studies proposed expanding the ‘‘E’’ of the CHARGE acronym to
encompass anomalies of the Extremities in order to draw attention
to CHARGE syndrome as a possible diagnosis for patients with limb
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defects [Alazami et al., 2008]. Other limb defects, including
triphalangeal thumb, polydactyly of the foot, monodactyly, radial
aplasia, and ectrodactyly have been seen in a minority of patients
[Jongmans et al., 2006; Van de Laar et al., 2007; Wright et al.,
2009]. Owing to small numbers of reported individuals, skeletal
differences between mutation-positive and mutation-negative
individuals were not examined in our study.
Immunological Abnormalities
Immunological problems are a rare feature of CHARGE syndrome,
with a small number of CHARGE patients described as having
thymic aplasia or hypoplasia, (sometimes called DiGeorge
‘‘syndrome’’) IgG2 subclass deficiency, and T-cell lymphopenia
[Writzl et al., 2007; Chopra et al., 2009; Jyonouchi et al., 2009].
Severe combined immune deficiency (SCID) has also been reported
in rare patients [Gennery et al., 2008]. Based on the small number of
cases, these clinical features were not included in our statistical
analysis.
CAN CLINICAL PRESENTATION PREDICT CHD7
MUTATION STATUS?
Here we summarized data from 379 individuals with clinical infor-
mation and CHD7 mutation status. We found that mutation-
positive individuals are more likely to have inner ear malformations
including semicircular canal aplasia/dysplasia, facial nerve palsy,
and ocular colobomas, and less likely to have delayed growth and
development. These data strongly support the use of temporal bone
CT as a diagnostic tool for evaluation of CHARGE patients, and
confirm previous reports that inner ear malformations should be
considered a diagnostic criterion.
In an earlier study of 110 clinically diagnosed CHARGE patients,
Lalani et al. [2006] compared phenotypic data from mutative-
positive and mutation-negative CHARGE patients and found that
mutation-positive patients were significantly more likely to
have cardiovascular defects, coloboma, and facial asymmetry
resulting from defects in cranial nerve VII. In contrast, no signi-
ficant differences were observed between the two groups in terms of
inner or outer ear anomalies, choanal atresia, cleft lip/palate,
deafness, tracheoesophageal fistula, and urogenital anomalies.
Interestingly, all 10 patients in the study who presented with the
combination of coloboma, choanal atresia, and hypoplastic
semicircular canals were found to have mutations in CHD7. Our
review of clinical data from 379 patients suggests that there is no
difference in frequency of heart defects, choanal atresia/stenosis,
genitourinary abnormalities, clefting, or trecheoesophageal
fistula between these two groups of individuals. Interestingly,
CHD7 mutation-positive patients also appear less likely to have
growth and developmental delays, and more likely to have facial
palsy compared with mutation-negative individuals.
Previous diagnostic criteria for CHARGE by Blake et al. [1998].
included ocular coloboma or microphthalmia, choanal atresia or
stenosis, characteristic inner and external ear anomalies, and cranial
nerve dysfunction as major criteria. Revised diagnostic criteria by
Verloes [2005] include ocular coloboma, choanal atresia/stenosis
and hypoplasia of the semicircular canals as major criteria. While
both sets of diagnostic criteria are used clinically, the utility of
subtypes such as atypical or partial CHARGE may be relatively low,
since these individuals can also present with a CHD7 mutation. In
that regard, it may be more helpful to estimate whether an indi-
vidual has an identifiable CHD7 mutation given the presence or
absence of the various CHARGE related clinical features. The full
spectrum of CHD7 mutation related phenotypes remain to be
determined, but can be explored using current massively parallel
rapid sequencing technologies.
CHD7
CHD7 belongs to the chromodomain helicase DNA binding
(CHD) family, one of four major families of ATP-dependent
chromatin remodeling proteins [Martens and Winston, 2003;
Corona and Tamkun, 2004; Denslow and Wade, 2007; Conaway
and Conaway, 2009]. The CHD protein family is evolutionarily
conserved in eukaryotes from the sole member, CHD1, in the yeast
Saccharomyces cerevisiae to the nine CHD proteins found in verte-
brates. CHD7 has homologs in several model organisms, including
Drosophila, zebrafish, and mouse. Studies of the CHD proteins in a
variety of in vivo and in vitro systems have yielded insights into
many functions of CHD proteins, including methylated histone
binding [Flanagan et al., 2005; Rodriguez-Paredes et al., 2009;
Schnetz et al., 2009], DNA binding [Stokes and Perry, 1995;
Bouazoune et al., 2002; Shur and Benayahu, 2005], transcriptional
regulation [Surapureddi et al., 2002, 2006; Ishihara et al., 2006;
Yuan et al., 2007; Rodriguez-Paredes et al., 2009; Schnetz et al.,
2009], cell cycle regulation [Biswas et al., 2008; Rodriguez-Paredes
et al., 2009], regulation of apoptosis [Bagchi et al., 2007; Nishiyama
et al., 2009], chromatin remodeling [Shur and Benayahu 2005; Lutz
et al., 2006; Stockdale et al., 2006; Denslow and Wade 2007;
Biswas et al., 2008; Thompson et al., 2008], and embryonic stem
cell pluripotency [Gaspar-Maia et al., 2009]. Two motifs define
members of this family: tandem N-terminal chromodomains,
responsible for binding methylated histones [Brehm et al.,
2004], and a central SNF2-like ATPase/helicase domain that
contains chromatin remodeling activity. While all nine members
share these domains, the family can be subdivided into three
subgroups based on the presence of additional domains [for review,
see Hall and Georgel, 2007; Marfella and Imbalzano, 2007].
The CHD7 gene is located on chromosome 8q12.1. Its genomic
structure spans 188 kb and encompasses 38 exons, the first of which
is noncoding. The encoded CHD7 protein (Fig. 1) is 2,997 amino
acids in length and has the tandem N-terminal chromodomains and
central helicase domain characteristic of members of the CHD
family. It also contains a C-terminal DNA binding domain that
shares a low degree of homology with the histone/DNA-binding
SANT domain [Cruz et al., 2005] as well as two C-terminal BRK
domains, the functions of which are currently unknown. Nuclear
localization is predicted due to the presence of these chromatin-
related domains as well as five consensus nuclear localization signals
(NLS). The nuclear localization of CHD7 has been experimentally
confirmed [Schnetz et al., 2009].
Expression analysis of CHD7 has been performed in human
[Sanlaville et al., 2006] and mouse embryos by in situ hybridization
[Bosman et al., 2005; Lalani et al., 2006],b-galactosidase expression
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[Hurd et al., 2007], and immunofluorescence [Adams et al., 2007;
Layman et al., 2009]. Expression of CHD7 is ubiquitous in human
fetal tissues by 22 days of development. Later in development,
CHD7 localizes to several tissues affected in CHARGE syndrome
including the developing ear, eye, and olfactory system. Expression
of Chd7 in the mouse embryo is generally consistent with
the patterns seen in human fetuses. Expression is widespread
and high early in development, with progressive restriction in
CHARGE-relevant tissues. In both mice and humans, the expres-
sion patterns of CHD7 are dynamic as development progresses,
suggesting that CHD7 expression during development is not only
tissue-specific but also temporally regulated.
CHD7 MUTANT MICE: MODELS OF
CHARGE SYNDROME
The first Chd7 mutant mice were reported by Bosman et al. [2005],
who characterized a set of nine mouse lines with ENU-induced
mutations on chromosome 4 that displayed dominant circling
behavior owing to inner ear defects. Sequence analysis revealed
that all mutations fell within the Chd7 gene. Interestingly, this
sequence analysis identified the mutations as truncating mutations
or splice site changes that were predicted to be loss-of-function.
Detailed analysis of Whirligig (Chd7Whi/þ), which carries a hetero-
zygous nonsense mutation in exon 11 (2918G!A leading to
W973X), demonstrated the presence of several CHARGE-like
features in adult mice and embryos. Chd7Whi/þ mice showed genital
defects including vulval hypoplasia and clitoral abnormalities in
94% of adult females, though no genital abnormalities were found
in mutant males. Forty-five percent of the mutant embryos dis-
played interventricular septal defects in the heart, a feature of
human CHARGE syndrome. Thirty-five percent of the mutant
mice displayed cleft palate or related palatal defects and choanal
defects were also seen in some mutant embryos. No optic colobo-
mas were found, though approximately 50% of the mutant mice
developed keratoconjunctivitis sicca. Truncation of the lateral
semicircular canal and circling behaviors were observed, consistent
with the vestibular dysfunction seen in human CHARGE patients.
The mean body weight of both male and female Chd7Whi/þmice was
significantly lower than wild-type controls, consistent with the
postnatal growth retardation observed in human CHARGE
patients.
Use of gene-trap technology to induce Chd7 deficiency in mice
has also yielded insights into some of the developmental defects of
CHARGE syndrome [Hurd et al., 2007]. The gene-trap strategy
used to disrupt Chd7 introduced a b-galactosidase expression
vector between exons 1 and 2 of the gene, resulting in a loss-of-
function Chd7 allele. Analysis of mice heterozygous for the
gene-trapped Chd7 allele (Chd7Gt/þ) showed that they recapitulate
the circling behavior observed with the ENU-induced mutants,
providing further support for vestibular dysfunction as a con-
sequence of Chd7 mutation. Chd7Gt/þ mice also display severe
inner ear defects, including truncation or hypoplasia of both the
lateral and posterior semicircular canals [Adams et al., 2007]. In
addition to inner ear defects in the Chd7Gt/þ mouse line, defects in
the olfactory system including olfactory dysfunction and olfactory
bulb hypoplasia were reported [Layman et al., 2009]. Chd7 is
expressed in the olfactory basal cells, which are the neural stem
cell population of the olfactory epithelium. BrdU incorporation
and immunofluorescence showed that CHD7 is expressed in pro-
liferating neural stem cells, and that Chd7Gt/þ mice have defects in
neural stem cell proliferation leading to a reduction in olfactory
sensory neuron production and regeneration. These results suggest
that CHD7 is required for the development and maintenance of the
olfactory epithelium. The olfactory anomalies seen in Chd7Gt/þ
mice also suggest that the olfactory dysfunction in humans with
CHARGE syndrome may be in part due to defects of the peripheral
olfactory system.
Analysis of the reproductive and olfactory abilities of
Chd7Whi/þ mice has shown further correlation with human
CHARGE phenotypes [Bergman et al., 2009]. Chd7Whi/þ mice have
severely reduced olfaction in a smell test and hypoplasia of the
olfactory bulb. Chd7Whi/þ mice have a reduction in GnRH neurons
in the hypothalamus and median eminence. A reduction in GnRH
neurons may contribute to the decrease in gonadotropins
commonly found in human CHARGE patients. Interestingly, the
mean testis weight of Chd7Whi/þ adult males was significantly
lower than wild-type controls and two males also showed severe
testicular hypoplasia. These results contrast a previous study of
Chd7Whi/þ mice, which showed no genital abnormalities in males
[Bosman et al., 2005]. Fertility was also significantly reduced in both
male and female Chd7Whi/þ mice.
It is currently unclear why mice with mutations in Chd7 display
some, but not all, features of human CHARGE syndrome. The
FIG. 1. A schematic representation of the CHD7 protein. Domains are depicted approximately to scale.
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phenotypic discrepancies between humans and mice with CHD7
mutations may simply reflect species-specific differences in the
developmental requirement for CHD7. However, it is also likely
that the genetic background of the mice plays a role. Genetic
modifiers in the genome may alter the penetrance and expressivity
of certain phenotypic features in both mice and in humans.
To address this question, the mutation could be crossed onto
several genetic backgrounds and the mutant progeny examined
for penetrance and expressivity of the various CHARGE
features. Interestingly, Chd7Gt/þ mice maintained on a C57BL/6J
background display a more severe ear phenotype while mice on a
129S1/Sv1mJ background display a more severe olfactory pheno-
type than Chd7Gt/þ mice maintained on a mixed background
(D.M.M., unpublished work).
MOLECULAR ANALYSIS OF CHD7 FUNCTION
In the eukaryotic cell, DNA is wrapped around basic protein
octamers composed of histones. In addition to a central globular
DNA-binding domain, histones have flexible N-terminal tails
that can be modified on many residues by a wide range of
enzymes. Modification of histone tails by methylation, acetylation,
ubiquitination, and other mechanisms exerts differential effects
on transcription [Kouzarides, 2007]. The structure of the CHD7
protein, which includes NLSs, domains for binding methylated
histones and DNA, and altering chromatin structure, indicates that
it is likely a nuclear protein with transcriptional regulatory
activity, acting as an effector for histone modifications. Accor-
dingly, molecular studies of CHD7 have thus far focused on its role
as a transcriptional regulator involved in recognizing histone
modifications and altering chromatin structure.
Recent genomic studies have provided functional insights into
CHD7 [Schnetz et al., 2009]. The chromodomains of CHD7 were
found to be functional and able to bind all methylated forms of
histone H3 lysine 4 (H3K4me) in vitro. The genomic distribution
of CHD7 on chromatin was mapped by chromatin immuno-
precipitation on tiled microarrays (ChIP-chip), a technique
designed to detect specific protein-DNA interactions. CHD7 bind-
ing was correlated closely with regions of H3K4 methylation,
characteristic of regions undergoing active transcription. A large
number of CHD7 binding sites also displayed characteristics similar
to enhancer elements, that is, they were marked with H3K4me1,
predominantly distal to transcriptional start sites, often contained
within regions of open chromatin, and located near genes
with relatively high levels of expression [Heintzman et al., 2007].
Moreover, several of the CHD7 binding sites were shown to
enhance the activity of luciferase reporter genes [Schnetz et al.,
2009]. Notably, binding of CHD7 to sites of H3K4me1 was
much stronger than binding to sites of H3K4me3, suggesting that
CHD7 binds strongly to enhancer elements and transiently loops
chromatin to transcription start sites to promote transcriptional
regulation (Fig. 2). This provides a possible mechanism by which
dysregulation of CHD7 target genes during embryonic develop-
ment could lead to CHARGE syndrome.
Studies of the Drosophila melanogaster ortholog of CHD7,
Kismet, also support a role for CHD7 as a transcriptional regulator
[Srinivasan et al., 2008]. Kismet was found to bind to chromatin at
transcriptional start sites and antagonize the establishment of
H3K27 trimethylation, a well-characterized repressive histone
modification [Schwartz and Pirrotta, 2007], to facilitate early
elongation by RNA polymerase II. Interestingly, the chromo-
domains of Kismet were unable to bind methylated H3K4 in vitro,
unlike the chromodomains of human CHD7 [Schnetz et al.,
2009]. While Kismet and mammalian CHD7 both appear to
function in transcriptional regulation, the mechanisms appear
to be different. Kismet binds to transcriptional start sites and
facilitates transcriptional elongation, while CHD7 binds to distal
enhancer elements and may loop chromatin to transcriptional
start sites to promote transcription and facilitate elongation. This
may reflect differences in CHD protein function between mammals
and insects. However, an alternative explanation for this dis-
crepancy is that Kismet is the D. melanogaster ortholog of not only
CHD7, but also CHD8 and CHD9 and that the loss of one CHD
protein may have a different functional consequence than loss
of all three. Further studies in mammalian cells with knockdown
of various combinations of CHD7, CHD8, and CHD9 are needed
to elucidate the functional conservation of these proteins with
Kismet.
FIG. 2. A model for CHD7 function. CHD7 binds to enhancer elements in the presence of protein cofactors and facilitates looping of chromatin to bring
the enhancer in close proximity with transcription start sites and allowing CHD7 and associated cofactors to modulate the transcriptional output of
the gene.
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DISCUSSION AND FUTURE DIRECTIONS
Perhaps the most important question regarding the pathogenesis of
CHARGE syndrome is how haploinsufficiency of CHD7 gives rise
to the specific defects seen in the disorder. Some insight into this
issue may come from the function of CHD7. Studies of CHD7
suggest that it has a role in regulating transcription through
enhancer elements. Enhancers are known to act with both tissue
and temporal specificity; thus, their activity may not be conserved
between cell types or developmental stages. It therefore seems likely
that CHD7 is required in the developing cell types that give rise
to CHARGE-affected tissues to regulate the expression of genes
affecting cell proliferation, differentiation, and migration. One
possibility is that 50% of the total CHD7 protein in these cell types
is insufficient to modulate transcription of these developmentally
important genes. However, this possibility may be simplistic, as
enhancer-mediated regulation of CHD7 target genes is likely to be
cofactor dependent. Recent studies in murine embryonic stem
cells have shown that up to five factors may be bound at certain
enhancer elements [Chen et al., 2008]. Transcriptional modulation
by enhancement may also be dependent on multiple enhancers,
as demonstrated for genes within the b-globin cluster and the
imprinted IGF2 and H19 loci [Tuan et al., 1985; Dhar et al.,
1990; Leighton et al., 1995; Webber et al., 1998]. Current knowledge
about CHD7 binding to enhancer elements predicts that loss of 50%
of CHD7 protein may impair binding of cofactors to chromatin,
looping of enhancers to transcriptional start sites, and/or modula-
tion of chromatin structure at transcriptional start sites. However,
further developmental and biochemical studies are needed to
delineate the roles of CHD7 in enhancer-mediated transcriptional
regulation in various tissues and developmental stages.
Based on analysis of human and mouse embryos, CHD7 expres-
sion is variable and dependent on tissue and developmental
time. This observation suggests that the requirements for CHD7
are dynamic, depending both on the tissue in question and the
developmental stage, and is consistent with the implication
of CHD7 in enhancer-mediated transcriptional regulation. To
address this challenging problem, mice with conditional knockouts
of Chd7 are being created to allow tissue- and temporal-specific
reduction of CHD7 levels and assessment of specific developmental
consequences of its loss (D.M.M., unpublished work).
Another important component to understanding the patho-
genesis of CHARGE syndrome will be discovering regulatory
targets of CHD7. Because current evidence suggests that CHD7
regulates transcription via enhancer elements, which may be
specific to a certain cell type, it stands to reason that CHD7 may
have a distinct set of target genes in individual cell types in specific
stages and tissues development. Uncovering these targets in the
cell types that give rise to CHARGE-affected tissues will be most
informative with regard to the regulatory role of CHD7 in
development.
Further molecular analysis of CHD7 is also needed to advance
our understanding of CHARGE syndrome. Chromatin remodeling
enzymes are generally found in large multiprotein complexes
[Vignali et al., 2000], and it seems likely that CHD7 interacts
with a specific set of proteins to achieve its regulatory
effects. Biochemical purification of this complex will provide
insights into the mechanism of transcriptional regulation by CHD7.
As mentioned previously, it is likely that CHD7 has different
protein partners in different cell types, allowing for diversity in its
transcriptional regulatory activity.
Together, mouse models of CHARGE syndrome and functional
studies of CHD7 have begun to provide molecular explanations
for the diverse clinical manifestations of CHARGE syndrome.
Continued study of the molecular functions of CHD7 and its
requirement in the development of embryonic tissues will be
important in advancing our understanding of this complex
condition.
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